prodchem
Jul 29, 2026
A shareholder holding roughly 2% of H.B. Fuller's stock is proving loud enough to shape the conversation around one of the company's biggest deals in years. Activist investor Ancora Holdings has publicly opposed H.B. Fuller's $943 million bid for UK-based Advanced Medical Solutions (AMS), arguing the acquisition contradicts a commitment the company had made earlier this year to slow down its pace of mergers and acquisitions. The dispute is a reminder that even strategically sound deals can run into resistance when they collide with a company's own recent promises to investors.
Ancora's position isn't primarily about whether AMS is a good business, it's about timing and trust. Earlier in 2026, some investors began publicly raising concerns about H.B. Fuller's debt load and cash position after the company completed 11 acquisitions in recent years under CEO Celeste Mastin. In response, H.B. Fuller signaled it would pull back on dealmaking. Ancora's opposition centers on the fact that the AMS bid arrived shortly after that signal, which the firm views as a break from what shareholders were led to expect.
This is a common activist investor playbook: rather than contesting the strategic logic of a specific target, the pressure is applied to management's capital allocation discipline and its follow-through on prior commitments to the market.
Mastin has been candid about the tension. In interviews following the announcement, she acknowledged being ready to pause acquisitions and "reload" the company's balance sheet, but said a rival bid for AMS, a company H.B. Fuller had reportedly been eyeing since 2023, forced a decision. Losing AMS to a competitor, in her framing, would have meant losing a scarce and structurally attractive asset in a market H.B. Fuller has identified as core to its long-term strategy.
That explanation hasn't fully quieted the opposition, but it does clarify the company's reasoning:
AMS represents a rare opportunity in a market H.B. Fuller considers structurally scarce, with high regulatory barriers limiting the pool of comparable acquisition targets.
Management believes the long-term margin and growth benefits outweigh the near-term optics of resuming M&A activity so soon after signaling restraint.
The company has pointed to its balance sheet trajectory, including improving net debt-to-EBITDA, as evidence it can absorb the deal without compromising financial discipline.
Investor unease showed up quickly in H.B. Fuller's share price, which fell roughly 14% in premarket trading the day the deal was announced, even though the company simultaneously beat second-quarter earnings expectations and raised its full-year adjusted EPS guidance. That combination, strong operating results paired with a sharp share price decline, is a fairly clear signal that the market's concern was less about AMS's fundamentals and more about capital allocation strategy and the credibility of management's prior guidance.
Net debt stood at roughly $1.96 billion at the time of the announcement, with net debt-to-adjusted EBITDA improving to 3.1x. Whether that leverage profile is sustainable through integration will likely remain a point of scrutiny from investors like Ancora throughout the deal's closing process.
Activist opposition holding a small equity stake rarely blocks a deal outright, but it does tend to increase scrutiny around execution. Companies facing this kind of pressure often respond by:
Providing more detailed integration timelines and synergy tracking to reassure the broader shareholder base.
Emphasizing deleveraging plans more explicitly in subsequent earnings communications.
Slowing the pace of any further acquisitions in the near term to rebuild credibility around capital discipline.
For a chemical or adhesives buyer watching from the outside, this kind of investor tension is less about whether the deal closes, it almost certainly will, and more about how quickly and smoothly H.B. Fuller can integrate AMS while managing its balance sheet and shareholder relationships simultaneously.
Shareholder disputes like this one rarely change the underlying commercial reality for buyers, but they're a useful signal of how much financial pressure a supplier is under during a period of integration. Procurement teams sourcing from either H.B. Fuller or AMS should keep an eye on the company's deleveraging progress and integration milestones over the coming quarters, since financial strain during a contested acquisition can sometimes translate into supply chain disruptions, account restructuring, or shifting commercial terms. Staying informed on the governance side of a deal is just as important as tracking the product and pricing implications.
Ready to source adhesive raw materials from verified global suppliers? Explore competitive offers on our platform today.
Featured Product
Found this useful?
Continue Reading
H.B. Fuller has closed 13 acquisitions since 2023 while simultaneously reducing its net debt-to-adjusted EBITDA ratio to 3.1x from 3.5x a year earlier. Here's how the company is defending its dealmaking pace against activist investor concerns, and what the numbers actually show.
FDA's Human Foods Program guidance agenda is increasingly extending beyond traditional food safety into chemical exposure, ingredient transparency and labeling. For manufacturers, packaging companies and chemical suppliers, the expanding agenda signals a need for stronger coordination between regulatory affairs, procurement, formulation control and supplier documentation.
The Covestro-led bio-based aniline project, backed by $8 million of its $10 million funding from the EU, reflects Europe's broader push to commercialize lower-carbon chemical production. The initiative highlights how public funding is increasingly being used to de-risk technologies that could reduce dependence on fossil feedstocks across major aromatic chemical value chains.
